Major Clinical Study Using Semler's QuantaFlo® for Medicare Advantage Beneficiaries, Demonstrates that National, In-Home Screening for Peripheral Artery Disease (PAD) is Feasible
SANTA CLARA, Calif., Dec. 14, 2022 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that a study was published in the peer-reviewed AJPM Focus with data collected using the company's QuantaFlo® PAD test under real-world conditions, illustrating the benefits of PAD in-home screening. AJPM Focus is the official open access journal jointly launched this year by both The American College of Preventive Medicine and the Association for Prevention Teaching and Research. The article, titled "Peripheral Artery Disease Screening in the Community and 1-Year Mortality, Cardiovascular Events, and Adverse Limb Events,"1 may be accessed through this link: https://www.sciencedirect.com/science/article/pii/S2773065422000141#sec0015.
The study analyzed screening tests using QuantaFlo® for Medicare Advantage beneficiaries aged ≥65 years participating in the Optum HouseCalls program in the U.S. between April 1, 2017 and February 1, 2019. Of the 192,500 patients tested in their homes, 27.7% had a positive result for PAD. One-year all-cause mortality, 1- and 2-year major adverse cardiovascular events (MACE), and major adverse limb events (MALE) in the PAD positive patients were all significantly increased versus those patients who screened negative for PAD (p
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.